**Table 1.1. Results of the univariable analyses comparing patients with history of mid-gastrointestinal bleeding who experienced an episode of rebleeding after small bowel capsule endoscopy (SBCE) *versus* those who had not rebled (Anemia subgroup)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | No Rebleeding after SBCE (*n*=206) | Rebleeding after SBCE (*n*=55) | Hazard ratio  (95%CI) | *P* value |
| Age (years) – n(%) |  |  |  | <0.001 |
| < 60 | 114 (55.6) | 9 (16.1) | a |  |
| > 60 | 91 (44.4) | 47 (83.9) | 6.2 (3.0-12.6) |  |
| Gender – *n* (%) |  |  |  | 0.017 |
| Female | 152 (81.7) | 34 (18.3) | a |  |
| Male | 53 (70.7) | 22 (29.3) | 1.9 (1.1-3.3) |  |
| Number of hospitalizations – *n* (%) |  |  |  | <0.001 |
| 0 | 43 (21.0) | 2 (3.6) | a |  |
| 1-4 | 114 (55.6) | 16 (28.6) | 2.7 (0.6-11.6) | 0.192 |
| > 5 | 48 (23.4) | 38 (67.9) | 11.3 (2.7-46.7) | 0.001 |
| Incomplete SBCE – *n* (%) | 12 (5.9) | 5 (8.9) | 1.3 (0.5-3.2) | 0.601 |
| Findings – *n* (%) |  |  |  |  |
| No findings | 95 (46.3) | 9 (16.1) | a |  |
| P0 lesions | 12 (5.9) | 5 (8.9) | 3.1 (1.0-9.3) | 0.044 |
| P1 lesions | 41 (20.0) | 17 (30.4) | 4.5 (2.0-10.0) | <0.001 |
| P2 lesions | 57 (27.8) | 25 (44.6) | 6.2 (2.9-13.5) | <0.001 |
| Type of lesions – *n* (%) |  |  |  |  |
| Nodules | 7 (3.4) | 0 (0) | 0.1 (0-29.8) | 0.352 |
| Lymphangiectasias | 4 (2.0) | 2 (3.6) | 1.1 (0.3-4.5) | 0.918 |
| Red spots | 6 (2.9) | 1 (1.8) | 0.7 (0.1-4.9) | 0.693 |
| Erosions | 36 (17.6) | 15 (26.8) | 1.6 (0.9-2.9) | 0.112 |
| Angioectasiae | 44 (21.5) | 20 (35.7) | 2.6 (1.5-4.6) | 0.001 |
| Ulcers | 12 (5.9) | 3 (5.4) | 1.3 (0.4-4.2) | 0.664 |
| Tumors | 1 (0.5) | 5 (8.9) | 5.1 (2.0-12.9) | 0.001 |
| Number of angioectasiae – *n* (%) |  |  |  | <0.001 |
| 0 | 161 (78.5) | 35 (62.5) | a |  |
| 1 | 29 (14.1) | 8 (14.3) | 1.9 (0.9-4.0) | 0.116 |
| > 2 | 15 (7.3) | 13 (23.2) | 4.2 (2.2-8.2) | <0.001 |
| Microcytosis – *n* (%) | 78 (38.0) | 29 (51.8) | 1.8 (1.1-3.0) | 0.031 |
| MHC < 30pg – *n* (%) | 178 (86.8) | 49 (87.5) | 0.9 (0.4-2.0) | 0.842 |
| MCHC < 33% – *n* (%) | 167 (81.5) | 49 (87.5) | 1.5 (0.7-3.2) | 0.341 |
| Thrombocytopenia – *n* (%) | 12 (5.9) | 6 (10.7) | 1.9 (0.8-4.4) | 0.144 |
| Drug use – *n* (%) |  |  |  |  |
| Anti-platelet agents | 55 (26.8) | 25 (44.6) | 2.1 (1.2-3.6) | 0.006 |
| Acetylsalicylic acid | 47 (22.9) | 23 (41.1) | 2.2 (1.3-3.8) | 0.004 |
| Clopidogrel | 4 (2.0) | 0 (0) | 0.1 (0-452.3) | 0.516 |
| Ticlopidine | 1 (0.5) | 1 (1.8) | 2.9 (0.4-20.7) | 0.301 |
| Anti-coagulants | 25 (12.2) | 20 (35.7) | 3.6 (2.1-6.2) | <0.001 |
| Warfarin | 23 (11.2) | 17 (30.4) | 3.0 (1.7-5.3) | <0.001 |
| Enoxaparin | 1 (0.5) | 3 (5.4) | 7.3 (2.2-23.7) | 0.001 |
| Proton pump inhibitors | 96 (46.8) | 40 (71.4) | 2.9 (1.6-5.1) | <0.001 |
| Selective serotonin reuptake inhibitors | 46 (22.4) | 14 (25.0) | 1.0 (0.6-1.8) | 0.988 |
| Charlson comorbidity index – *n* (%) |  |  |  |  |
| 0 | 55 (26.8) | 5 (8.9) | a |  |
| ]0-5[ | 93 (45.4) | 10 (17.9) | 1.2 (0.4-3.4) | 0.794 |
| > 5 | 57 (27.8) | 41 (73.2) | 7.0 (2.8-17.8) | <0.001 |
| Hypertension – *n* (%) | 101 (49.3) | 46 (82.1) | 4.3 (2.1-8.5) | <0.001 |
| Dyslipidemia – *n* (%) | 84 (41.0) | 35 (62.5) | 2.3 (1.3-4.0) | 0.002 |
| Heart failure – *n* (%) | 40 (19.5) | 23 (58.9) | 5.2 (3.0-8.9) | <0.001 |
| Cardiac ischemic disease – *n* (%) | 24 (11.7) | 11 (19.6) | 2.1 (1.1-4.1) | 0.026 |
| Aortic stenosis – *n* (%) | 10 (4.9) | 7 (12.5) | 2.6 (1.2-5.9) | 0.017 |
| Chronic liver disease – *n* (%) | 9 (4.4) | 6 (10.7) | 2.0 (0.9-4.8) | 0.100 |
| Severe chronic liver disease | 1 (0.5) | 2 (3.6) | 10.3 (2.4-43.8) | 0.002 |
| Peripheral arterial disease – *n* (%) | 5 (2.4) | 3 (5.4) | 3.8 (1.2-12.3) | 0.031 |
| Cerebrovascular disease – *n* (%) | 24 (11.7) | 5 (8.9) | 0.9 (0.4-2.2) | 0.811 |
| Type 2 diabetes mellitus – *n* (%) | 57 (27.8) | 21 (37.5) | 1.7 (1.0-2.9) | 0.057 |
| Diabetes with target organ lesion – *n* (%) | 11 (5.4) | 11 (19.6) | 3.1 (1.6-5.9) | 0.001 |
| Thyroid disease – *n* (%) | 36 (17.6) | 5 (8.9) | 0.7 (0.3-1.7) | 0.372 |
| Solid neoplasm – *n* (%) | 37 (18.0) | 16 (28.6) | 1.7 (1.0-3.1) | 0.072 |
| Metastasized neoplasms | 6 (2.9) | 2 (3.6) | 1.3 (0.3-5.4) | 0.710 |
| Chronic kidney disease – *n* (%) | 40 (19.5) | 26 (46.4) | 3.9 (2.3-6.6) | <0.001 |
| Class 4 or 5 | 10 (4.9) | 4 (7.1) | 1.4 (0.5-3.9) | 0.498 |
| Chronic obstructive pulmonary disease – *n* (%) | 14 (6.8) | 15 (26.8) | 4.0 (2.2-7.2) | <0.001 |
| Dementia – *n* (%) | 7 (3.4) | 4 (7.1) | 1.9 (0.7-5.2) | 0.235 |
| Hemiparesis – *n* (%) | 1 (0.5) | 0 (0) | 0.5 (0-40533) | 0.664 |
| Connective tissue disease – *n* (%) | 11 (5.4) | 2 (3.6) | 0.6 (0.1-2.3) | 0.415 |
| Tobacco consumption – *n* (%) | 25 (12.2) | 17 (30.4) | 3.1 (1.7-5.5) | <0.001 |
| Alcoholism – *n* (%) | 9 (4.4) | 5 (8.9) | 2.8 (1.1-7.1) | 0.028 |
| Peptic ulcer – *n* (%) | 11 (5.4) | 3 (5.4) | 1.1 (0.3-3.5) | 0.883 |
| Major bleeding – *n* (%) | 75 (36.6) | 51 (91.1) | 12.1 (4.8-30.2) | <0.001 |
| “Major bleeding event” b – *n* (%) | 1 (0.5) | 3 (5.4) | 2.7 (0.8-8.6) | 0.097 |
| More than 2 transfusions – *n* (%) | 69 (33.7) | 50 (89.3) | 10.5 (4.5-24.5) | <0.001 |
| Hemoglobin fall > 2 g/L – *n* (%) | 74 (36.1) | 50 (89.3) | 10.3 (4.4-24.1) | <0.001 |
| Endoscopic treatment – *n* (%) | 11 (5.4) | 16 (28.6) | 5.1 (2.8-9.2) | <0.001 |

CI=Confidence interval; a Reference group; b Symptomatic bleeding in a critical organ

**Table 1.1. Results of the univariable analyses comparing patients with history of mid-gastrointestinal bleeding who experienced an episode of rebleeding after small bowel capsule endoscopy (SBCE) *versus* those who had not rebled (Overt bleeding subgroup)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | No Rebleeding after SBCE (*n*=64) | Rebleeding after SBCE (*n*=32) | Hazard ratio  (95%CI) | *P* value |
| Age (years) – n(%) |  |  |  | 0.093 |
| < 60 | 18 (28.1) | 5 (15.6) | a |  |
| > 60 | 46 (71.9) | 27 (84.4) | 2.3 (0.9-5.9) |  |
| Gender – *n* (%) |  |  |  | 0.830 |
| Female | 29 (65.9) | 15 (34.1) | a |  |
| Male | 35 (67.3) | 17 (32.7) | 0.9 (0.4-1.9) |  |
| Number of hospitalizations – *n* (%) |  |  |  | <0.001 |
| 0 | 6 (9.4) | 1 (3.1) | a |  |
| 1-4 | 41 (64.1) | 9 (28.1) | 1.4 (0.2-11.0) | 0.757 |
| > 5 | 17 (26.6) | 22 (68.8) | 5.8 (0.8-43.2) | 0.086 |
| Incomplete SBCE – *n* (%) | 4 (6.3) | 7 (21.9) | 3.6 (1.5-8.4) | 0.003 |
| Findings – *n* (%) |  |  |  |  |
| No findings | 14 (21.9) | 7 (21.9) | a |  |
| P0 lesions | 7 (10.9) | 0 (0) | 0 (0-/) | 0.975 |
| P1 lesions | 18 (28.1) | 4 (12.5) | 0.6 (0.2-2.2) | 0.482 |
| P2 lesions | 25 (39.1) | 21 (65.6) | 1.8 (0.8-4.3) | 0.176 |
| Type of lesions – *n* (%) |  |  |  |  |
| Nodules | 1 (1.6) | 0 (0) | 0.1 (0-/) | 0.945 |
| Lymphangiectasias | 4 (6.3) | 0 (0) | 0.1 (0-33.0) | 0.355 |
| Red spots | 1 (1.6) | 0 (0) | 0.1 (0-/) | 0.745 |
| Erosions | 16 (25.0) | 4 (12.5) | 0.5 (0.2-1.5) | 0.249 |
| Angioectasiae | 23 (35.9) | 16 (50.0) | 2.0 (1.0-4.0) | 0.062 |
| Ulcers | 2 (3.1) | 3 (9.4) | 1.4 (0.4-4.9) | 0.609 |
| Tumors | 1 (1.6) | 2 (6.3) | 2.0 (0.5-8.7) | 0.333 |
| Number of angioectasiae – *n* (%) |  |  |  |  |
| 0 | 41 (64.1) | 15 (46.9) | a |  |
| 1 | 9 (14.1) | 9 (28.1) | 2.3 (1.0-5.2) | 0.057 |
| > 2 | 14 (21.9) | 8 (25.0) | 2.0 (0.8-4.8) | 0.124 |
| Microcytosis – *n* (%) | 22 (34.4) | 14 (43.8) | 1.3 (1.1-2.6) | 0.479 |
| MHC < 30pg – *n* (%) | 47 (73.4) | 21 (65.6) | 0.6 (0.3-1.2) | 0.165 |
| MCHC < 33% – *n* (%) | 46 (71.9) | 23 (71.9) | 0.8 (0.4-1.8) | 0.672 |
| Thrombocytopenia – *n* (%) | 6 (9.4) | 4 (12.5) | 1.5 (0.5-4.4) | 0.439 |
| Drug use – *n* (%) |  |  |  |  |
| Anti-platelet agents | 28 (43.8) | 11 (34.4) | 1.1 (0.5-2.3) | 0.826 |
| Acetylsalicylic acid | 21 (32.8) | 6 (18.8) | 0.8 (0.3-2.0) | 0.639 |
| Clopidogrel | 5 (7.8) | 3 (9.4) | 1.6 (0.5-5.2) | 0.459 |
| Ticlopidine | 1 (1.6) | 0 (0) | 0 (0-/) | 0.804 |
| Anti-coagulants | 16 (25.0) | 4 (12.5) | 0.5 (0.2-1.6) | 0.263 |
| Warfarin | 13 (20.3) | 4 (12.5) | 0.7 (0.2-2.0) | 0.492 |
| Enoxaparin | 2 (3.1) | 0 (0) | 0.5 (0-/) | 0.572 |
| Proton pump inhibitors | 38 (59.4) | 25 (78.1) | 2.3 (1.0-5.7) | 0.063 |
| Selective serotonin reuptake inhibitors | 11 (17.2) | 7 (21.9) | 0.8 (0.3-1.9) | 0.598 |
| Charlson comorbidity index – *n* (%) |  |  |  |  |
| 0 | 5 (7.8) | 1 (3.1) | a |  |
| ]0-5[ | 24 (37.5) | 6 (18.8) | 1.4 (0.2-11.9) | 0.773 |
| > 5 | 35 (54.7) | 25 (78.1) | 4.1 (0.5-31.0) | 0.175 |
| Hypertension – *n* (%) | 41 (64.1) | 23 (71.9) | 2.2 (1.0-5.0) | 0.056 |
| Dyslipidemia – *n* (%) | 31 (48.4) | 19 (59.4) | 1.9 (0.9-4.0) | 0.072 |
| Heart failure – *n* (%) | 20 (31.3) | 18 (56.3) | 3.2 (1.6-6.6) | 0.001 |
| Cardiac ischemic disease – *n* (%) | 12 (18.8) | 8 (25.0) | 1.7 (0.8-3.8) | 0.198 |
| Aortic stenosis – *n* (%) | 6 (9.4) | 6 (18.8) | 1.9 (0.8-4.7) | 0.157 |
| Chronic liver disease – *n* (%) | 4 (6.3) | 2 (6.3) | 1.2 (0.3-5.3) | 0.763 |
| Severe chronic liver disease | 2 (3.1) | 2 (6.3) | 2.0 (0.5-8.4) | 0.352 |
| Peripheral arterial disease – *n* (%) | 2 (3.1) | 5 (15.6) | 1.9 (0.7-4.9) | 0.207 |
| Cerebrovascular disease – *n* (%) | 7 (10.9) | 6 (18.8) | 1.5 (0.6-3.6) | 0.398 |
| Type 2 diabetes mellitus – *n* (%) | 22 (34.4) | 11 (34.4) | 1.2 (0.6-2.5) | 0.666 |
| Diabetes with target organ lesion – *n* (%) | 4 (6.3) | 7 (21.9) | 3.4 (1.4-8.0) | 0.006 |
| Thyroid disease – *n* (%) | 8 (12.5) | 2 (6.3) | 0.7 (0.2-3.0) | 0.635 |
| Solid neoplasm – *n* (%) | 21 (32.8) | 10 (31.3) | 1.0 (0.5-2.1) | 0.938 |
| Metastasized neoplasms | 5 (7.8) | 1 (3.1) | 0.5 (0.1-3.6) | 0.490 |
| Chronic kidney disease – *n* (%) | 17 (26.6) | 14 (43.8) | 3.5 (1.7-7.2) | 0.001 |
| Class 4 or 5 | 4 (6.3) | 2 (6.3) | 1.3 (0.3-5.6) | 0.711 |
| Chronic obstructive pulmonary disease – *n* (%) | 5 (7.8) | 2 (6.3) | 1.2 (0.3-5.1) | 0.816 |
| Dementia – *n* (%) | 4 (6.3) | 5 (15.6) | 3.9 (1.5-10.6) | 0.007 |
| Hemiparesis – *n* (%) | 0 (0) | 1 (3.1) | 5.8 (0.8-44.3) | 0.091 |
| Connective tissue disease – *n* (%) | 1 (1.6) | 2 (6.3) | 1.9 (0.4-7.9) | 0.391 |
| Tobacco consumption – *n* (%) | 16 (25.0) | 13 (40.6) | 2.2 (1.1-4.6) | 0.038 |
| Alcoholism – *n* (%) | 6 (9.4) | 3 (9.4) | 1.2 (0.4-3.9) | 0.801 |
| Peptic ulcer – *n* (%) | 11 (17.2) | 4 (12.5) | 0.8 (0.3-2.2) | 0.599 |
| Major bleeding – *n* (%) | 44 (68.8) | 30 (93.8) | 6.4 (1.5-26.9) | 0.011 |
| “Major bleeding event” b – *n* (%) | 2 (3.1) | 1 (3.1) | 1.8 (0.2-13.5) | 0.560 |
| More than 2 transfusions – *n* (%) | 44 (68.8) | 30 (93.8) | 6.2 (1.5-26.1) | 0.013 |
| Hemoglobin fall > 2 g/L – *n* (%) | 45 (70.3) | 30 (93.8) | 6.2 (1.5-26.1) | 0.013 |
| Endoscopic treatment – *n* (%) | 4 (6.3) | 14 (43.8) | 2.9 (1.4-5.8) | 0.004 |

CI=Confidence interval; a Reference group; b Symptomatic bleeding in a critical organ